Reta

Reta

Overview: Reta is an experimental tritagonist drug targeting three hormone receptors: GLP-1, GIP, and glucagon. It is designed to mimic these hormones' effects, such as enhancing satiety, regulating blood sugar, and suppressing appetite.

Product Specification:

• Purity: >99% (HPLC verified)
• Formulation: Lyophilized powder for reconstitution
• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight: 4845.44 g/mol
• CAS Number: 2381089-83-2
• PubChem SID: 474492335

Product Features:

• Tritagonist: Interacts with GLP-1, GIP, and glucagon receptors.
• Regulates appetite and blood sugar levels.
• Administered via specific receptors in the brain and gut.

Research Applications:

• Obesity Treatment: Clinical trials have shown significant weight loss with once-weekly treatment.
• Diabetes Management: Aims to improve glucose control, beneficial for type 2 diabetes management.

Conclusion: Reta presents a promising approach for obesity and diabetes treatment, offering a novel mechanism of action through a triple-receptor agonist profile. It's a significant development in the search for more effective treatments for these conditions.

Important Notice: This product is designated for research purposes only and is not approved for human consumption. It should be handled by qualified professionals, strictly for in vitro research and educational purposes.

COA Batch 2381-0524-5HHT (5mg)

Batch 2381-0524-5HHT